Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Nicklaus Children's Hospital
mi
from
Miami, FL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Nicklaus Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
All Children's Hospital
mi
from
Saint Petersburg, FL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Saint Joseph's Hospital/Children's Hospital-Tampa
mi
from
Tampa, FL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Saint Joseph's Hospital/Children's Hospital-Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Kansas Cancer Center
mi
from
Kansas City, KA
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Kansas Cancer Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Michigan State University Clinical Center
mi
from
East Lansing, MI
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Michigan State University Clinical Center
mi
from
East Lansing, MI
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
The Mayo Clinic
mi
from
Rochester, MN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Morristown Medical Center
mi
from
Morristown, NJ
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Morristown Medical Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
New York Medical College
mi
from
Valhalla, NY
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Children's Hospital Medical Center of Akron
mi
from
Akron, OH
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Children's Hospital Medical Center of Akron
mi
from
Akron, OH
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Dayton Children's Hospital
mi
from
Dayton, OH
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Dayton Children's Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Greenville Cancer Treatment Center
mi
from
Greenville, SC
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Greenville Cancer Treatment Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Marshfield Clinic
mi
from
Marshfield, WI
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated:  4/8/2016
Royal Brisbane and Women's Hospital
mi
from
Herston,
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
A Study of Neurocognitive Function in Children Treated for ALL
Status: Enrolling
Updated: 4/8/2016
Royal Brisbane and Women's Hospital
mi
from
Herston,
Click here to add this to my saved trials
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated:  4/11/2016
City of Hope
mi
from
Duarte, CA
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated: 4/11/2016
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated:  4/11/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated: 4/11/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated:  4/11/2016
Loyola University Medical Center
mi
from
Maywood, IL
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated: 4/11/2016
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated:  4/11/2016
Massachusetts General Hospital
mi
from
Boston, MA
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated: 4/11/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated:  4/11/2016
Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program
mi
from
Boston, MA
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated: 4/11/2016
Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program
mi
from
Boston, MA
Click here to add this to my saved trials
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated:  4/11/2016
Boston Children's Hospital
mi
from
Boston, MA
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated: 4/11/2016
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated:  4/11/2016
University of Michigan
mi
from
Ann Arbor, MI
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated: 4/11/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated:  4/11/2016
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated: 4/11/2016
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated:  4/11/2016
Oregon Health Sciences
mi
from
Portland, OR
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated: 4/11/2016
Oregon Health Sciences
mi
from
Portland, OR
Click here to add this to my saved trials
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated:  4/11/2016
Mount Sinai Hosp
mi
from
New York, NY
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.
Status: Enrolling
Updated: 4/11/2016
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Southern California Permanente Medical Group
mi
from
Downey, CA
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Southern California Permanente Medical Group
mi
from
Downey, CA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Children's Hospital Central California
mi
from
Madera, CA
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Children's Hospital Central California
mi
from
Madera, CA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Childrens National Medical Center
mi
from
Washington,
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated:  4/12/2016
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Status: Enrolling
Updated: 4/12/2016
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Click here to add this to my saved trials